New combo therapy shows promise for Tough-to-Treat prostate cancer
NCT ID NCT02225704
First seen Apr 14, 2026 · Last updated Jun 12, 2026 · Updated 9 times
Summary
This study tested a combination of two drugs, Radium-223 and enzalutamide, in 45 men with advanced prostate cancer that had spread and was no longer responding to hormone therapy. The goal was to see if the combination was safe and tolerable. Researchers tracked side effects and how long it took for the cancer to progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cork University Hospital
Cork, Ireland
-
Galway University Hospital
Galway, Ireland
-
Mater Misericordiae University Hospital
Dublin, Ireland
-
Mater Private Hospital
Dublin, Ireland
-
SLRON, St James's Hospital
Dublin, Ireland
-
St Vincents University Hospital / AMNCH
Dublin, Ireland
-
Tallaght Hospital
Dublin, Ireland
Conditions
Explore the condition pages connected to this study.